We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+24.54%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$278M
AUM Growth
+$61.2M
Cap. Flow
+$17.6M
Cap. Flow %
6.32%
Top 10 Hldgs %
51.21%
Holding
67
New
9
Increased
19
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.7M
2
MRK icon
Merck
MRK
+$7.14M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.27M
4
HALO icon
Halozyme
HALO
+$4.42M
5
BIIB icon
Biogen
BIIB
+$3.88M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$17M
2
INSM icon
Insmed
INSM
+$6.57M
3
PTCT icon
PTC Therapeutics
PTCT
+$5.18M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.7M
5
INCY icon
Incyte
INCY
+$2.78M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
Vertex Pharmaceuticals
VRTX
$139B
$20.4M 7.36%
93,422
+9,400
+11% +$1.9M
GILD icon
2
Gilead Sciences
GILD
$185B
$19.1M 6.86%
293,284
-23,000
-7% -$1.5M
AMGN icon
3
Amgen
AMGN
$236B
$15.9M 5.73%
66,000
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$5.13B
$14.4M 5.18%
336,000
+268,000
+394% +$11.7M
NBIX icon
5
Neurocrine Biosciences
NBIX
$15.8B
$14.3M 5.16%
133,300
-14,000
-10% -$1.47M
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$14.1M 5.08%
390,000
+172,000
+79% +$5.27M
BIIB icon
7
Biogen
BIIB
$32.7B
$13.6M 4.88%
45,700
+14,000
+44% +$3.88M
REGN icon
8
Regeneron Pharmaceuticals
REGN
$83.1B
$10.8M 3.9%
28,830
-11,000
-28% -$3.7M
STML
9
DELISTED
Stemline Therapeutics, Inc.
STML
$10.3M 3.69%
965,245
+130,000
+16% +$1.29M
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$9.31M 3.35%
86,141
-16,000
-16% -$1.71M
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$12.6B
$8.81M 3.18%
104,284
+17,000
+19% +$1.28M
ILMN icon
12
Illumina
ILMN
$34.3B
$8.32M 3%
25,803
– –
AMRN
13
Amarin Corp
AMRN
$297M
$8.31M 3%
19,400
+6,450
+50% +$2.45M
MRK icon
14
Merck
MRK
$369B
$7.55M 2.72%
+86,984
New +$7.14M
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
$7.31M 2.63%
64,000
-2,400
-4% -$255K
INCY icon
16
Incyte
INCY
$25.9B
$5.59M 2.01%
64,000
-32,500
-34% -$2.78M
PTCT icon
17
PTC Therapeutics
PTCT
$5.99B
$5.47M 1.97%
114,000
-122,000
-52% -$5.18M
HALO icon
18
Halozyme
HALO
$12.1B
$5.45M 1.96%
307,633
+255,000
+484% +$4.42M
SRPT icon
19
Sarepta Therapeutics
SRPT
$2.28B
$5.17M 1.86%
40,100
+14,000
+54% +$1.41M
ALNY icon
20
Alnylam Pharmaceuticals
ALNY
$31.6B
$4.99M 1.8%
43,300
+9,500
+28% +$947K
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
$4.92M 1.77%
277,433
+100,000
+56% +$1.31M
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.63M 1.67%
35,900
+25,000
+229% +$2.41M
IONS icon
23
Ionis Pharmaceuticals
IONS
$10.4B
$3.25M 1.17%
53,781
+7,600
+16% +$453K
NKTR icon
24
Nektar Therapeutics
NKTR
$2.55B
$3.02M 1.09%
9,333
+5,333
+133% +$1.55M
XLRN
25
DELISTED
Acceleron Pharma
XLRN
$3.02M 1.09%
57,000
+27,000
+90% +$1.23M
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2019 Portfolio in Review

As of Q4 2019, International Biotechnology Trust held 67 positions worth $278M, up 28% from $216M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

International Biotechnology Trust deployed $17.6M of net new capital in Q4 2019, opening 9 new positions and adding to 19 existing holdings. Its largest new stake was Merck: 86,984 shares worth $7.55M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $6.57M trimmed.

  • International Biotechnology Trust's largest Q4 2019 buy was Merck: 86,984 shares worth $7.55M.
  • International Biotechnology Trust added most to Acadia Pharmaceuticals in Q4 2019, an estimated $11.7M increase.
  • International Biotechnology Trust's biggest Q4 2019 reduction was Insmed, cutting an estimated $6.57M.
  • International Biotechnology Trust fully exited Celgene Corp in Q4 2019, selling an estimated $17M.
  • International Biotechnology Trust's ten largest holdings make up 51% of its $278M portfolio in Q4 2019.
  • International Biotechnology Trust opened 9 new positions and closed 4 in Q4 2019.
  • International Biotechnology Trust's portfolio value rose 28% quarter-over-quarter to $278M.

Based on International Biotechnology Trust's 13F filing for Q4 2019, filed 18 May 2020.